Literature DB >> 15165001

Recent developments in Graves' ophthalmopathy imaging.

G J Kahaly1.   

Abstract

Orbital ultrasound, computed tomography, and magnetic resonance are commonly used as imaging techniques to demonstrate pathological changes in ocular adnexa of patients with Graves' ophthalmopathy. Low cost, short time of investigation, and lack of radiation characterize ultrasound. Nevertheless, a clear differentiation regarding disease activity is not possible, nor is the evaluation of orbital tissue precise enough. Short investigation time, precise imaging of the orbital apex and moderate costs are advantages of tomography. This method delivers a significant radiation dose to the lens, which if repeated constitutes a risk for cataract development. For this reason, magnetic resonance imaging is preferable, particularly if repeated scans are required to assess response to treatment. Precise tissue differentiation and lack of ionizing radiation uniquely suit magnetic resonance for eye studies. Although sensitive in demonstrating interstitial edema within the rectos muscles in active disease, as well as providing a good predictive value with respect to immunosuppressive therapy, quantitative magnetic resonance imaging is an expensive method and is non-specific for the orbital changes in ophthalmopathy. Because of a favorable target to background ratio, octreoscan carries a high sensitivity and may be regarded as a semi-objective tool in the evaluation of patients with Graves' ophthalmopathy, both at initial stages as well as during treatment. A positive orbital octreoscan indicates a clinically active disease in which immunosuppressive treatment might be of therapeutic benefit. However, it is an expensive method with a non-negligible radiation burden. Also, it is neither specific nor does it offer detailed orbital imaging. In summary, in unclear cases of proptosis or recently developed diplopia, prior to orbital decompression surgery, or if imaging is needed in subjects with ophthalmopathy, magnetic resonance actually is the imaging method of choice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15165001     DOI: 10.1007/BF03345274

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  37 in total

1.  Graves ophthalmopathy: role of MR imaging in radiation therapy.

Authors:  M Just; G Kahaly; H P Higer; H P Rösler; J Kutzner; J Beyer; M Thelen
Journal:  Radiology       Date:  1991-04       Impact factor: 11.105

2.  Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey.

Authors:  A P Weetman; W M Wiersinga
Journal:  Clin Endocrinol (Oxf)       Date:  1998-07       Impact factor: 3.478

Review 3.  Neuroradiological diagnosis in thyroid-associated orbitopathy.

Authors:  W Müller-Forell; S Pitz; W Mann; G J Kahaly
Journal:  Exp Clin Endocrinol Diabetes       Date:  1999       Impact factor: 2.949

4.  Comparison of standardized echography with magnetic resonance imaging to measure extraocular muscle size.

Authors:  J L Demer; B M Kerman
Journal:  Am J Ophthalmol       Date:  1994-09-15       Impact factor: 5.258

5.  Graves orbitopathy: correlation of CT and clinical findings.

Authors:  R A Nugent; R I Belkin; J M Neigel; J Rootman; W D Robertson; J Spinelli; D A Graeb
Journal:  Radiology       Date:  1990-12       Impact factor: 11.105

6.  Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.

Authors:  R Moncayo; I Baldissera; C Decristoforo; D Kendler; E Donnemiller
Journal:  Thyroid       Date:  1997-02       Impact factor: 6.568

7.  A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves ophthalmopathy.

Authors:  M F Prummel; M S Suttorp-Schulten; W M Wiersinga; A M Verbeek; M P Mourits; L Koornneef
Journal:  Ophthalmology       Date:  1993-04       Impact factor: 12.079

8.  Volume measurements of normal orbital structures by computed tomographic analysis.

Authors:  G Forbes; D G Gehring; C A Gorman; M D Brennan; I T Jackson
Journal:  AJR Am J Roentgenol       Date:  1985-07       Impact factor: 3.959

9.  [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?

Authors:  P T Postema; E P Krenning; R Wijngaarde; P P Kooy; H Y Oei; W A van den Bosch; J C Reubi; W M Wiersinga; H Hooijkaas; T van der Loos
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

10.  Correlation of CT scanning and pathologic features of ophthalmic Graves' disease.

Authors:  S L Trokel; F A Jakobiec
Journal:  Ophthalmology       Date:  1981-06       Impact factor: 12.079

View more
  4 in total

1.  Thyroid-associated orbitopathy.

Authors:  Adel H Alsuhaibani; Jeffrey A Nerad
Journal:  Semin Plast Surg       Date:  2007-02       Impact factor: 2.314

Review 2.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

3.  [Graves' ophthalmopathy].

Authors:  A Eckstein; J Esser
Journal:  Internist (Berl)       Date:  2010-05       Impact factor: 0.743

4.  Graves' ophthalmopathy: the role of diffusion-weighted imaging in detecting involvement of extraocular muscles in early period of disease.

Authors:  R Kilicarslan; A Alkan; M M Ilhan; H Yetis; A Aralasmak; E Tasan
Journal:  Br J Radiol       Date:  2014-12-19       Impact factor: 3.039

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.